NEUROENDOCRINE MECHANISMS OF WEIGHT RECOVERY AFTER WITHDRAWAL OF GLP-1 RECEPTOR AGONISTS: AN INTEGRATIVE REVIEW
DOI:
https://doi.org/10.56238/revgeov17n3-184Keywords:
Obesity, GLP-1 Receptor Agonists, Metabolic Adaptation, Weight RegainAbstract
The aim of this study is to analyze the metabolic adaptation processes and hormonal changes in obese patients after the use of GLP-1 receptor agonists, aiming to identify the factors that influence weight regain. The methodology consisted of an integrative literature review, based on scientific articles published between 2015 and 2025, indexed in databases such as PubMed, LILACS, and BDENF. The analysis of the 11 selected studies allowed us to examine the adverse biological reactions to weight loss, focusing on the dynamics between leptin and ghrelin and the effectiveness of long-term therapeutic maintenance. The results indicate that continuous medical follow-up is fundamental in the management of obesity, especially regarding the mitigation of adaptive thermogenesis and the compensatory increase in hunger after drug discontinuation. Strategies such as maintaining pharmacotherapy, health education on the chronicity of the disease, and monitoring basal energy expenditure proved effective in promoting the maintenance of lost weight and improving the cardiometabolic health of patients. The study reaffirms that, due to neuroendocrine adaptations that drive weight regain, obesity should be treated as a chronic disease. Therefore, the need for clinical protocols that prioritize maintenance therapy to improve the clinical outcome of patients with metabolic resistance to weight loss is highlighted.
Downloads
References
ARONNE, L. J. et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA, v. 331, n. 1, p. 38–48, 2024.
GARVEY, T. W. et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, v. 28, n. 10, p. 2083–2091, 2022.
HOPKINS, M.; BLUNDELL, J. E. Metabolic adaptation, weight loss and energy balance: a theoretical review. Journal of Clinical Medicine, v. 12, n. 11, p. 3701, 2023.
LEIBEL, R. L. et al. Changes in energy expenditure resulting from altered body weight. The New England Journal of Medicine, v. 332, n. 10, p. 621–628, 1995.
MENDES, K. D. S.; SILVEIRA, R. C. C. P.; GALVÃO, C. M. Revisão integrativa: método de pesquisa para a incorporação de evidências na saúde e na enfermagem. Texto & Contexto - Enfermagem, v. 17, n. 4, p. 758-764, 2008.
MÜLLER, M. J. et al. Metabolic adaptation to weight loss: implications for the customized treatment of obesity. Endocrine Reviews, v. 42, n. 3, p. 256–281, 2021.
PAGE, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ, v. 372, n. 71, 2021.
RUBINO, F. et al. Role of the gastrointestinal tract in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology, v. 9, n. 4, p. 234-245, 2021.
RYAN, D. H. et al. Next-generation pharmacotherapy for obesity: reducing the burden of disease. The Lancet, v. 402, n. 10411, p. 1475–1491, 2023.
WHARTON, S. et al. Weight loss maintenance in overweight and obese adults: a systematic review. Journal of Obesity, v. 2020, ID 6415282, 2020.
WILDING, J. P. H. et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine, v. 384, n. 11, p. 989-1002, 2021.
WILDING, J. P. H. et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, v. 24, n. 8, p. 1553–1564, 2022.
ZANG, H. et al. GLP-1 Receptor Agonists and the Risk of Weight Regain: A Meta-Analysis. Clinical Endocrinology, v. 98, n. 2, p. 112-120, 2023.
